0000899243-22-021633.txt : 20220609 0000899243-22-021633.hdr.sgml : 20220609 20220609170609 ACCESSION NUMBER: 0000899243-22-021633 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220607 FILED AS OF DATE: 20220609 DATE AS OF CHANGE: 20220609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DOUGLAS RICHARD CENTRAL INDEX KEY: 0001021015 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 221006792 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-07 0 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001021015 DOUGLAS RICHARD C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE LEXINGTON MA 02421 1 0 0 0 Stock Option (Right to Buy) 3.60 2022-06-07 4 A 0 53812 0.00 A 2032-06-06 Common Stock 53812 53812 D Stock Option (Right to Buy) 3.60 2022-06-07 4 A 0 13917 0.00 A 2032-06-06 Common Stock 13917 13917 D Stock Option (Right to Buy) 3.60 2022-06-07 4 A 0 1624 0.00 A 2032-06-06 Common Stock 1624 1624 D Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. /s/ Richard Douglas 2022-06-09